Table 2 HER2 expression in gastric cancer: analysing studies with patients from different parts of the world
Study | Year | Patients’ place of origin | Number of patients | HER2 positive rate (%) | Association with clinicopathological features |
|---|---|---|---|---|---|
Bang YJ [6] | 2010 | ToGA trial (Multicenter) | 3,665 | 16.6 | Topography (GEJ) |
Intestinal-type | |||||
Begnami MD [19] | 2011 | Brazil (Single center) | 221 | 8.0 | Intestinal-type |
Low-grade | |||||
Cruz-Reyes C [45] | 2013 | Mexico (Single center) | 269 | 3.7 | Intestinal-type |
Cho J [32] | 2013 | South Korea (Single center) | 2,798 | 7.3 | Older age |
Male gender | |||||
Intestinal-type | |||||
Upper-third stomach | |||||
Higher lymph node stage | |||||
Advanced staging | |||||
Shan L [17] | 2013 | China (Single center) | 1,463 | 9.8 | Topography (GEJ) |
Intestinal-type | |||||
Low-grade | |||||
Matsusaka S [35] | 2015 | Japan (Multicenter) | 1,461 | 15.6 | Intestinal-type |
Hepatic metastasis | |||||
Absence of peritoneal metastasis | |||||
Cappellesso R [34] | 2015 | Europe (Multicenter) | 1,040 | 11.0 | Intestinal-type |
Low-grade | |||||
Laboissiere RS | 2015 | Brazil (Single Center) | 124 | 10.5 | Intestinal-type |
Low-grade | |||||
Lymphovascular invasion |